Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients

OncoImmunology

Volumn 1, Issue 4, 2012, Pages 432-440

  Manuel, Manuarii ^a,b,c,d   Trédan, Olivier ^d   Bachelot, Thomas ^d   Clapisson, Gilles ^d   Courtier, Anais ^a   Parmentier, Gilles ^a   Rabeony, Tioka ^a   Grives, Audrey ^a   Perez, Solène ^a   Mouret, Jean François ^a   Perol, David ^d   Chabaud, Sylvie ^d   Ray Coquard, Isabelle ^d   Labidi Galy, Intidhar ^d   Heudel, Pierre ^d   Pierga, Jean Yves ^e   Caux, Christophe ^b,c,d   Blay, Jean Yves ^b,c,d   Pasqual, Nicolas ^a   Ménétrier Caux, Christine ^b,c,d  

^a CEA GRENOBLE   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CNRS   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT CURIE   (France)

Author keywords

Divpenia; First line chemotherapy; Lymphodivpenia; Lymphopenia; Metatastatic breast cancer; Overall survival

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMOGLOBIN; HORMONE RECEPTOR; LACTATE DEHYDROGENASE;

ACCURACY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOLOGICAL PARAMETERS; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; NUMERATION AND DIVERSITY OF LYMPHOCYTE SCORE; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SEMI QUANTITATIVE MULTI N PLEX POLYMERASE CHAIN REACTION; T CELL REPERTOIRE DIVERSITY; VALIDATION PROCESS;

EID: 84870767920     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19545     Document Type: Article

References (41)

1. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14:636-643; PMID:8636781
2. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998; 92:405-410; PMID:9657738
3. Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004; 101:2675-2680; PMID:15503313; http://dx.doi.org/10.1002/cncr.20688
4. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al and ELYPSE study group. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88:181-186; PMID:12610500; http://dx.doi.org/10.1038/sj.bjc.6600724
5. Ray-Coquard I, Ghesquière H, Bachelot T, Borg C, Biron P, Sebban C, et al and ELYPSE Study Group. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001; 85:816-822; PMID: 11556830; http://dx.doi.org/10.1054/bjoc.2001.2011
6. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al and European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009; 69:5383-5391; PMID:19549917; http://dx.doi.org/10.1158/0008-5472.CAN-08-3845
7. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-1955; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
8. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71:5423-5434; PMID:21697280; http://dx.doi.org/10.1158/0008-5472.CAN-11-0367
9. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92:4778-4791; PMID:9845545
10. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-7474; PMID:15569976; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684
11. Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, Goutagny N, et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res 2011; 71:6143-6152; PMID:21852386; http://dx.doi.org/10.1158/0008-5472.CAN-11-0573
12. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69:2000-2009; PMID:19244125; http://dx.doi.org/10.1158/0008-5472.CAN-08-2360
13. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
14. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37:473-484; PMID:21074063; http://dx.doi.org/10.1053/j.seminoncol.2010.09.001
15. Hesslein DG, Schatz DG. Factors and forces controlling V(D)J recombination. Adv Immunol 2001; 78: 169-232; PMID:11432204; http://dx.doi.org/10.1016/S0065-2776(01)78004-2
16. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302:575-581; PMID:6300689; http://dx.doi.org/10.1038/302575a0
17. Marodon G, Desjardins D, Mercey L, Baillou C, Parent P, Manuel M, et al. High diversity of the immune repertoire in humanized NOD.SCID. gamma c-/- mice. Eur J Immunol 2009; 39:2136-2145; PMID:19572320; http://dx.doi.org/10.1002/eji.200939480
18. Pasqual N, Gallagher M, Aude-Garcia C, Loiodice M, Thuderoz F, Demongeot J, et al. Quantitative and qualitative changes in V-J alpha rearrangements during mouse thymocytes differentiation: implication for a limited T cell receptor alpha chain repertoire. J Exp Med 2002; 196:1163-1173; PMID:12417627; http://dx.doi.org/10.1084/jem.20021074
19. Pham HP, Manuel M, Petit N, Klatzmann D, Cohen-Kaminsky S, Six A, et al. Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice. Eur J Immunol 2011; Epub ahead of print; PMID:22105329; http://dx.doi.org/10.1002/eji.201141798.
20. Gorochov G, Neumann AU, Kereveur A, Parizot C, Li T, Katlama C, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998; 4:215-221; PMID:9461196; http://dx.doi.org/10.1038/nm0298-215
21. Palermo B, Del Bello D, Sottini A, Serana F, Ghidini C, Gualtieri N, et al. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res 2010; 70:7084-7092; PMID: 20823160; http://dx.doi.org/10.1158/0008-5472.CAN-10-1326
22. Capellino AR, Desposorio CR, Hurtado de Mendoza F, et al. Lymphopenia and breast cancer subtypes as prognostic factors in patients with locally advanced breast cancer. ASCO Meeting, 29 2011 e21100(Abstract)
23. Cézé N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 2011; 68:1305-1313; PMID:21448592; http://dx.doi.org/10.1007/s00280-011-1610-3
24. Luo W, Liao WJ, Huang YT, Shi M, Zhang Y, Wen Q, et al. Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy. Cancer Sci 2011; 102:706-712; PMID:21235683; http://dx.doi.org/10.1111/j.1349-7006.2011.01868.x
25. Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B, et al. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci U S A 2010; 107:10632-10637; PMID: 20498045; http://dx.doi.org/10.1073/pnas.1000027107
26. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203:1701-1711; PMID: 16818678; http://dx.doi.org/10.1084/jem.20060772
27. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007; PMID:19287090
28. Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Targeted Oncology 2012; 7:55-68; PMID:2238042; http://dx.doi.org/10.1007/s11523-012-0210-4
29. Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205:1701-1714; PMID:18573906; http://dx.doi.org/10.1084/jem.20071681
30. Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee N, Zujewski J, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997; 90:3789-3798; PMID:9345067
31. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84:2221-2228; PMID:7919339
32. Ferrando-Martínez S, Franco JM, Hernandez A, Ordoñez A, Gutierrez E, Abad A, et al. Thymopoiesis in elderly human is associated with systemic inflammatory status. Age (Dordr) 2009; 31:87-97; PMID: 19507053; http://dx.doi.org/10.1007/s11357-008-9084-x
33. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, et al and AIDS Clinical Trials Group. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis 2006; 194:1098-1107; PMID: 16991084; http://dx.doi.org/10.1086/507313
34. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007; 28:1067-1073; PMID:17183065; http://dx.doi.org/10.1093/carcin/bgl250
35. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006; 8:190-198; PMID:16611412; http://dx.doi.org/10.1593/neo.05733
36. Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK, Gooding W, Lotze M, et al. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001; 7(Suppl):947s-957s; PMID:11300496
37. Agrawal S, Marquet J, Delfau-Larue MH, Copie-Bergman C, Jouault H, Reyes F, et al. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest 1998; 102: 1715-1723; PMID:9802885; http://dx.doi.org/10.1172/JCI3784
38. Grossman H. AIDS at 25: a quarter century of medical miracles. MedGenMed 2006; 8:57; PMID:16926796
39. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147:62-70; PMID: 12100186; http://dx.doi.org/10.1046/j.1365-2133.2002.04867.x
40. Chen CH, George SL. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med 1985; 4:39-46; PMID: 3857702; http://dx.doi.org/10.1002/sim.4780040107
41. Dahm PF, Gail MH, Rosenberg PS, Pee D. Determining the value of additional surrogate exposure data for improving the estimate of an odds ratio. Stat Med 1995; 14:2581-2598; PMID:8746890; http://dx.doi.org/10.1002/sim.4780142307